Sort by
Refine Your Search
-
Category
-
Country
-
Employer
- Leiden University
- Medical University of Lublin
- University of Oslo
- Delft University of Technology (TU Delft)
- Duke University
- Fundación Investigación del Cáncer Universidad de Salamanca
- GSI Helmholtzzentrum für Schwerionenforschung
- Institute for bioengineering of Catalonia, IBEC
- KTH Royal Institute of Technology
- La Rochelle Université
- Radboud University
- The University of Iowa
- Universidade de Coimbra
- Universitat Pompeu Fabra
- Universitat de Barcelona
- University of East Anglia
- 6 more »
- « less
-
Field
-
POSTDOCTORAL SCHOLAR Requisition # 4525 Position Basics Advertising Ends on:Monday, January 5th, 2026 Advertising Started on:Monday, December 22nd, 2025 College:College of Dentistry
-
to early phase clinical trials. We collaborate with investigators intramurally (Duke Pharmacology & Cancer Biology, Cell Biology, Biomedical Engineering), and extramurally nationally and internationally
-
markers, control Marfan and OKD48 mouse colonies; surgery for extraction of various organs. The candidate will join the lab of Gustavo Egea (Vascular Cell Biology Lab), which is currently comprised of 1
-
single-cell proteomics approaches on patient samples to gain additional resolution on cell-state diversity within tumours. In parallel, you will collaborate closely with a postdoctoral researcher to
-
the project and supervise day-to-day laboratory activities. Perform in vitro experiments on bone implants using cell cultures, including primary human cells and established cell lines. Assess cell
-
the SAMURAI, a national project in collaboration with Philips Medical Systems. You will be part of a diverse and passionate research team of academic staff, PhD candidates and Postdoctoral researchers in
-
to biological and pharmacological evaluation and formulation activities (WP2–WP3). The postdoctoral researcher recruited will play a key role in the scientific implementation of the project within LIENSs/BCBS and
-
Each year, approximately 6,000 people in the UK are diagnosed with multiple myeloma. Despite advances in therapy, infections remain a leading cause of morbidity and early mortality in these patients
-
) as a multifunctional tool for bone treatment and regeneration. Such biomaterials will respond to a static magnetic field (SMF), enhancing the differentiation of mesenchymal stem cells and osteoblasts
-
: 1st Jan 2026 or when agreed Description: The emerging ‘Synthetic Cell Programming’ lab, led by Dr. Santos-Moreno (santosmorenolab.org ), is seeking for a highly-motivated postdoctoral researcher